It has been suggested that autonomous activation of the downstream insulin signaling pathway as a treatment strategy for patients carrying the mutation (p.E17K) should be considered [29], since the ATK2 protein has crucial functions in the insulin signaling pathway and defective insulin signaling pathway leads to metabolic syndrome, IR and T2D [30,31,32]. Here, INS is linked to metabolic syndrome.